# Treatment of ANCA-Associated Glomerulonephritis Complicated by Bacteremia and Vertebral Osteomyelitis: A Challenging Medical Situation

## TL;DR

This paper discusses the challenges of treating a 77-year-old patient with ANCA-associated glomerulonephritis who developed severe infections and complications.

## Contribution

The paper presents a case study highlighting the risks of immunosuppressive treatment and introduces emerging therapies like avacopan and the DANGER score.

## Key findings

- Older age is independently associated with mortality and severe complications in AAV patients.
- Emerging therapies and predictive tools may help manage treatment intensity and reduce risks.
- Severe infections like bacteremia and osteomyelitis can occur in immunosuppressed AAV patients.

## Abstract

Although the prognosis for patients with ANCA-associated vasculitis (AAV) has improved with modern immunosuppressive drugs, treatment-related complications continue to contribute significantly to morbidity and mortality. Infections, in particular, pose a major risk. Older age, high disease activity at diagnosis, and use of potent immunosuppressants are the most important prognostic factors. Older age is independently associated with mortality, severe renal failure, pulmonary hemorrhage, and relapse. This case highlights the challenge of balancing effective immunosuppression with the associated increased risk of infection. A 77-year-old male treated for MPO-ANCA–positive crescentic glomerulonephritis developed severe complications, including bacteremia, osteomyelitis, and disseminated herpes zoster, ultimately resulting in septic shock. Emerging therapies such as avacopan and predictive tools such as the Death in ANCA Glomerulonephritis–Estimating the Risk (DANGER) score may help clinicians better navigate these complex scenarios by guiding treatment intensity and minimizing risks.